OncoCyte Corporation

NasdaqCM OCX

OncoCyte Corporation Dividend Per Share for the Trailing 12 Months (TTM) ending September 30, 2024

OncoCyte Corporation Dividend Per Share is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Dividend per share represents the dividends distributed per share. Indicates dividend yield potential on a per-share basis.

OncoCyte Corporation Dividend Per Share for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -0.00.
OncoCyte Corporation Dividend Per Share for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -0.00, a -100.00% change year over year.

Key data

Date	Dividend Per Share	Free Cash Flow Per Share	Return on Assets (ROA)	Return on Equity (ROE)

NasdaqCM: OCX

OncoCyte Corporation

CEO	Mr. Joshua Riggs
IPO Date	Dec. 30, 2015
Location	United States
Headquarters	15 Cushing
Employees	43
Sector	Healthcare
Industries Biotechnology

Description

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Key trends

Past 5 years